{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:31:33Z","timestamp":1792812693783,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100031688","name":"Pfizer Pharma GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031688","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Duchenne muscular dystrophy (DMD) is a rare genetic disorder that primarily\u00a0affects males. Beginning in childhood, patients experience ambulatory loss, heart failure and need ventilation. Disease management has improved, however, DMD remains debilitating, and has no cure. The rarity of the disease makes research difficult, and German prevalence data are lacking. Cost and resource utilization estimations are based on small sample sizes or self-reported data, limiting generalizability and adds the potential for recall bias. With a retrospective study on a healthcare claims database, we adapted algorithms to identify DMD patients and categorized them by disease stages 1\u20134 (early ambulatory, late ambulatory, early non-ambulatory, late non-ambulatory) with increasing disease progression. We analyzed annual prevalence, burden of disease, healthcare resource utilization and direct medical care costs, by time under observation (patient year).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>From 2016 to 2021, we identified 134 patients for which we could determine a disease stage and determined an extrapolated prevalence of DMD in Germany between 14.85 (95%CI 12.17, 17.95) and 18.91 (95%CI 15.70, 22.61) per 100,000 males under 40\u00a0years of age. Most patients we identified met DMD stage 4 group criteria (4<jats:italic>7<\/jats:italic>.01%), followed by stage 3 (3<jats:italic>7<\/jats:italic>.31%), stage 2 (33.58%) and only 4.48% in stage 1. The average age increased with progressing disease, from 4.27\u00a0years in stage 1, to 11.43, 18.86 and 23.21 in stage groups 2, 3 and 4, respectively. In the stage 2 group, diagnosis codes reflecting mobility support and orthopedic surgical interventions (15.56% of the group) were documented. In the stage 3 group, decubitus prevention was documented, increasing to around half of patients in the stage 4 group. Total direct mean healthcare costs per patient year increased substantially with disease severity group, from \u20ac2,180.73 (SD 16,258.90) in stage 1; \u20ac13,599.83 (SD 33,756.07) in stage 2; \u20ac14,472.08 (SD 27,245.78) in stage 3 and finally \u20ac41,888.70 (SD 117,718.13) in stage 4. Especially in stage groups 3 and 4, medical aids accounted for about half of total costs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>We present an algorithm on which further research can be based, and provide a current picture of epidemiology, burden of disease and healthcare utilization and direct costs of DMD in Germany.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03906-x","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T12:45:35Z","timestamp":1755089135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Epidemiology, disease burden and costs of Duchenne muscular dystrophy in Germany: an observational, retrospective health claims data analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Joanna","family":"Diesing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janbernd","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Pechmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Kunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarcyane Barata","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7617-6641","authenticated-orcid":false,"given":"Carolina","family":"Schwedhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsta","family":"Militzer-Horstmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivonne","family":"H\u00e4nsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Kisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"3906_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17:251\u201367. https:\/\/doi.org\/10.1016\/S1474-4422(18)30024-3.","journal-title":"Lancet Neurol"},{"key":"3906_CR2","unstructured":"Rubin M. Duchenne-Muskeldystrophie und Becker-Muskeldystrophie: Ausgabe f\u00fcr medizinische Fachkreise. 2022. https:\/\/www.msdmanuals.com\/de-de\/profi\/p%C3%A4diatrie\/angeborene-muskelkrankheiten\/duchenne-muskeldystrophie-und-becker-muskeldystrophie. Accessed 01\/2022."},{"key":"3906_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3233\/JND-160185","volume":"3","author":"J Vry","year":"2016","unstructured":"Vry J, Gramsch K, Rodger S, Thompson R, Steffensen BF, Rahbek J, et al. European cross-sectional survey of current care practices for Duchenne muscular dystrophy reveals regional and age-dependent differences. J Neuromuscul Dis. 2016;3:517\u201327. https:\/\/doi.org\/10.3233\/JND-160185.","journal-title":"J Neuromuscul Dis"},{"key":"3906_CR4","unstructured":"Orphanet: Das Portal f\u00fcr seltene Krankheiten und Orphan Drugs. Muskeldystrophie Typ Duchenne. https:\/\/www.orpha.net\/de\/disease\/detail\/98896#menu. Accessed November 2024."},{"key":"3906_CR5","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.nmd.2009.01.005","volume":"19","author":"P Brabec","year":"2009","unstructured":"Brabec P, Vondr\u00e1cek P, Klimes D, Baumeister S, Lochm\u00fcller H, Pavl\u00edk T, Gregor J. Characterization of the DMD\/BMD patient population in Czech Republic and Slovakia using an innovative registry approach. Neuromuscul Disord. 2009;19:250\u20134. https:\/\/doi.org\/10.1016\/j.nmd.2009.01.005.","journal-title":"Neuromuscul Disord"},{"key":"3906_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","volume":"12","author":"S Ryder","year":"2017","unstructured":"Ryder S, Leadley RM, Armstrong N, Westwood M, Kock S, Butt T, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12:79. https:\/\/doi.org\/10.1186\/s13023-017-0631-3.","journal-title":"Orphanet J Rare Dis"},{"key":"3906_CR7","doi-asserted-by":"publisher","first-page":"e2304","DOI":"10.1212\/WNL.0000000000012910","volume":"97","author":"J Broomfield","year":"2021","unstructured":"Broomfield J, Hill M, Guglieri M, Crowther M, Abrams K. Life expectancy in Duchenne muscular dystrophy: reproduced individual patient data meta-analysis. Neurology. 2021;97:e2304\u201314. https:\/\/doi.org\/10.1212\/WNL.0000000000012910.","journal-title":"Neurology"},{"key":"3906_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13023-014-0210-9","volume":"9","author":"O Schreiber-Katz","year":"2014","unstructured":"Schreiber-Katz O, Klug C, Thiele S, Schorling E, Zowe J, Reilich P, et al. Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany. Orphanet J Rare Dis. 2014;9:210. https:\/\/doi.org\/10.1186\/s13023-014-0210-9.","journal-title":"Orphanet J Rare Dis"},{"key":"3906_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77\u201393. https:\/\/doi.org\/10.1016\/S1474-4422(09)70271-6.","journal-title":"Lancet Neurol"},{"key":"3906_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17:347\u201361. https:\/\/doi.org\/10.1016\/S1474-4422(18)30025-5.","journal-title":"Lancet Neurol"},{"key":"3906_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1474-4422(09)70272-8","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9:177\u201389. https:\/\/doi.org\/10.1016\/S1474-4422(09)70272-8.","journal-title":"Lancet Neurol"},{"key":"3906_CR12","unstructured":"European Medicines Agency (EMA). Translarna. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/translarna. Accessed 2 Jun 2025."},{"key":"3906_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","volume":"15","author":"S Crisafulli","year":"2020","unstructured":"Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifir\u00f2 G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15:141. https:\/\/doi.org\/10.1186\/s13023-020-01430-8.","journal-title":"Orphanet J Rare Dis"},{"key":"3906_CR14","unstructured":"Verband der Ersatzkassen (vdek). Daten zum Gesundheitswesen: Versicherte. 2025. https:\/\/www.vdek.com\/presse\/daten\/b_versicherte.html. Accessed 23 May 2025."},{"key":"3906_CR15","doi-asserted-by":"publisher","first-page":"adv00309","DOI":"10.2340\/00015555-3655","volume":"100","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder S, Ketz M, Kossack N, Akumo D, Pignot M, Gabriel S, Chavda R. Epidemiology of Prurigo Nodularis compared with Psoriasis in Germany: a claims database analysis. Acta Derm Venereol. 2020;100:adv00309. https:\/\/doi.org\/10.2340\/00015555-3655.","journal-title":"Acta Derm Venereol"},{"key":"3906_CR16","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM). ICD-10-GM. 21\/10\/2024. https:\/\/www.bfarm.de\/EN\/Code-systems\/Classifications\/ICD\/ICD-10-GM\/_node.html. Accessed 21 Oct 2024."},{"key":"3906_CR17","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM). ATC-Klassifikation. 21\/10\/2024. https:\/\/www.bfarm.de\/DE\/Kodiersysteme\/Klassifikationen\/ATC\/_node.html. Accessed 21 Oct 2024."},{"key":"3906_CR18","unstructured":"Institut der deutschen Wirtschaft K\u00f6ln, REHADAT. GKV-Hilfsmittelverzeichnis. 28\/10\/2024. https:\/\/www.rehadat-gkv.de\/. Accessed 28 Oct 2024."},{"key":"3906_CR19","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM). OPS. 21\/10\/2024. https:\/\/www.bfarm.de\/EN\/Code-systems\/Classifications\/OPS-ICHI\/OPS\/_node.html. Accessed 21 Oct 2024."},{"key":"3906_CR20","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.18553\/jmcp.2023.29.9.1033","volume":"29","author":"R Schrader","year":"2023","unstructured":"Schrader R, Posner N, Dorling P, Senerchia C, Chen Y, Beaverson K, et al. Development and electronic health record validation of an algorithm for identifying patients with Duchenne muscular dystrophy in US administrative claims. J Manag Care Spec Pharm. 2023;29:1033\u201344. https:\/\/doi.org\/10.18553\/jmcp.2023.29.9.1033.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"3906_CR21","first-page":"633","volume":"23","author":"S Thayer","year":"2017","unstructured":"Thayer S, Bell C, McDonald C. The direct cost of managing a rare disease: assessing medical and pharmacy costs associated with Duchenne muscular dystrophy in the United States. J Manag Care Spec Pharm. 2017;23(6):633\u201341.","journal-title":"J Manag Care Spec Pharm"},{"key":"3906_CR22","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1017\/S1047951118002226","volume":"29","author":"JH Soslow","year":"2019","unstructured":"Soslow JH, Hall M, Burnette WB, Hor K, Chisolm J, Spurney C, et al. Creation of a novel algorithm to identify patients with Becker and Duchenne muscular dystrophy within an administrative database and application of the algorithm to assess cardiovascular morbidity. Cardiol Young. 2019;29:290\u20136. https:\/\/doi.org\/10.1017\/S1047951118002226.","journal-title":"Cardiol Young"},{"key":"3906_CR23","unstructured":"Darras BT, Urion DK, Ghosh PS. Dystrophinopathies. 2000. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1119\/. Accessed 16 Jun 2022."},{"key":"3906_CR24","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.nmd.2020.09.031","volume":"30","author":"M Janisch","year":"2020","unstructured":"Janisch M, Boehme K, Thiele S, Bock A, Kirschner J, Schara U, et al. Tasks and interfaces in primary and specialized palliative care for Duchenne muscular dystrophy: a patients\u2019 perspective. Neuromuscul Disord. 2020;30:975\u201385. https:\/\/doi.org\/10.1016\/j.nmd.2020.09.031.","journal-title":"Neuromuscul Disord"},{"key":"3906_CR25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.18553\/jmcp.2017.23.6.633","volume":"23","author":"S Thayer","year":"2017","unstructured":"Thayer S, Bell C, McDonald CM. The direct cost of managing a rare disease: assessing medical and pharmacy costs associated with Duchenne muscular dystrophy in the United States. J Manag Care Spec Pharm. 2017;23:633\u201341. https:\/\/doi.org\/10.18553\/jmcp.2017.23.6.633.","journal-title":"J Manag Care Spec Pharm"},{"key":"3906_CR26","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/jnnp.2008.158329","volume":"80","author":"AY Manzur","year":"2009","unstructured":"Manzur AY, Muntoni F. Diagnosis and new treatments in muscular dystrophies. J Neurol Neurosurg Psychiatry. 2009;80:706\u201314. https:\/\/doi.org\/10.1136\/jnnp.2008.158329.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3906_CR27","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1007\/s12325-022-02117-1","volume":"39","author":"J Iff","year":"2022","unstructured":"Iff J, Zhong Y, Gupta D, Paul X, Tuttle E, Henricson E, Schrader R. Disease progression stages and burden in patients with Duchenne muscular dystrophy using administrative claims supplemented by electronic medical records. Adv Ther. 2022;39:2906\u201319. https:\/\/doi.org\/10.1007\/s12325-022-02117-1.","journal-title":"Adv Ther"},{"key":"3906_CR28","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00246-021-02807-7","volume":"43","author":"C Villa","year":"2022","unstructured":"Villa C, Auerbach SR, Bansal N, Birnbaum BF, Conway J, Esteso P, et al. Current practices in treating cardiomyopathy and heart failure in duchenne muscular dystrophy (DMD): Understanding care practices in order to optimize DMD heart failure through ACTION. Pediatr Cardiol. 2022;43:977\u201385. https:\/\/doi.org\/10.1007\/s00246-021-02807-7.","journal-title":"Pediatr Cardiol"},{"key":"3906_CR29","doi-asserted-by":"publisher","unstructured":"Lee-Gannon T, Lehrenbaum H, Sheth R, P.A. Mammen P. Clinical Management of DMD-associated cardiomyopathy. In: Mattsson G, Magnusson P, editors. Cardiomyopathy: Disease of the heart muscle. Erscheinungsort nicht ermittelbar: 2021. https:\/\/doi.org\/10.5772\/intechopen.98919.","DOI":"10.5772\/intechopen.98919"},{"key":"3906_CR30","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/(SICI)1097-0258(19970415)16:7<791::AID-SIM500>3.0.CO;2-#","volume":"16","author":"MP Fay","year":"1997","unstructured":"Fay MP, Feuer EJ. Confidence intervals for directly standardized rates: a method based on the gamma distribution. Stat Med. 1997;16:791\u2013801.","journal-title":"Stat Med"},{"key":"3906_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011381","volume":"97","author":"A Fayssoil","year":"2018","unstructured":"Fayssoil A, Ogna A, Chaffaut C, Lamothe L, Ambrosi X, Nardi O, et al. Natural history of cardiac function in Duchenne and Becker muscular dystrophies on home mechanical ventilation. Medicine (Baltimore). 2018;97: e11381. https:\/\/doi.org\/10.1097\/MD.0000000000011381.","journal-title":"Medicine (Baltimore)"},{"key":"3906_CR32","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s13311-018-0648-x","volume":"15","author":"ML Chu","year":"2018","unstructured":"Chu ML, Moran E. The limb-girdle muscular dystrophies: Is treatment on the horizon? Neurotherapeutics. 2018;15:849\u201362. https:\/\/doi.org\/10.1007\/s13311-018-0648-x.","journal-title":"Neurotherapeutics"},{"key":"3906_CR33","unstructured":"Gis\u00e8le Bonne, France Leturcq, Rabah Ben Yaou. Emery-Dreifuss Muscular Dystrophy. In: Bonne G, Leturcq F, Yaou RB, editors. GeneReviews\u00ae: University of Washington, Seattle; 2019."},{"key":"3906_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s41669-023-00450-x","volume":"8","author":"J Broomfield","year":"2024","unstructured":"Broomfield J, Hill M, Chandler F, Crowther MJ, Godfrey J, Guglieri M, et al. Developing a natural history model for Duchenne muscular dystrophy. Pharmacoecon Open. 2024;8:79\u201389. https:\/\/doi.org\/10.1007\/s41669-023-00450-x.","journal-title":"Pharmacoecon Open"},{"key":"3906_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0960-8966(99)00055-3","volume":"10","author":"N Darin","year":"2000","unstructured":"Darin N, Tulinius M. Neuromuscular disorders in childhood: a descriptive epidemiological study from western Sweden. Neuromuscul Disord. 2000;10:1\u20139. https:\/\/doi.org\/10.1016\/s0960-8966(99)00055-3.","journal-title":"Neuromuscul Disord"},{"key":"3906_CR36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/s1090-3798(03)00077-1","volume":"7","author":"U-A Talkop","year":"2003","unstructured":"Talkop U-A, Kahre T, Napa A, Talvik I, S\u00f6\u00f6t A, Piirsoo A, et al. A descriptive epidemiological study of Duchenne muscular dystrophy in childhood in Estonia. Eur J Paediatr Neurol. 2003;7:221\u20136. https:\/\/doi.org\/10.1016\/s1090-3798(03)00077-1.","journal-title":"Eur J Paediatr Neurol"},{"key":"3906_CR37","doi-asserted-by":"publisher","first-page":"S701","DOI":"10.1016\/j.jval.2019.09.1587","volume":"22","author":"E Giegerich","year":"2019","unstructured":"Giegerich E, Stuntz M. PMS43 Duchenne muscular dystrophy prevalence in five European countries: A novel incidence-based modeling approach using system dynamics. Value Health. 2019;22:S701. https:\/\/doi.org\/10.1016\/j.jval.2019.09.1587.","journal-title":"Value Health"},{"key":"3906_CR38","doi-asserted-by":"crossref","unstructured":"Labisa P, Andreozzi V, Mota M, Monteiro S, Alves R, Almeida J, et al. Cost of illness in patients with Duchenne muscular dystrophy in Portugal: The COIDUCH Study. PharmacoEconomics. 2021.","DOI":"10.1186\/s12955-022-01941-x"},{"key":"3906_CR39","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/WNL.0000000000000669","volume":"83","author":"E Landfeldt","year":"2014","unstructured":"Landfeldt E, Lindgren P, Bell CF, Schmitt C, Guglieri M, Straub V, et al. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology. 2014;83:529\u201336. https:\/\/doi.org\/10.1212\/WNL.0000000000000669.","journal-title":"Neurology"},{"key":"3906_CR40","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3233\/JND-221527","volume":"10","author":"Y Fang","year":"2023","unstructured":"Fang Y, McDonald CM, Clemens PR, Gordish H-D, Illei K, Hoffman EP, Dang UJ. Modeling early heterogeneous rates of progression in boys with Duchenne muscular dystrophy. J Neuromuscul Dis. 2023;10:349\u201364. https:\/\/doi.org\/10.3233\/JND-221527.","journal-title":"J Neuromuscul Dis"},{"key":"3906_CR41","doi-asserted-by":"publisher","first-page":"1360224","DOI":"10.3389\/fgene.2024.1360224","volume":"15","author":"F Gatto","year":"2024","unstructured":"Gatto F, Benemei S, Piluso G, Bello L. The complex landscape of DMD mutations: moving towards personalized medicine. Front Genet. 2024;15:1360224. https:\/\/doi.org\/10.3389\/fgene.2024.1360224.","journal-title":"Front Genet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03906-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03906-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03906-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:50:01Z","timestamp":1757422201000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03906-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3906"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03906-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"21 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JD, TG, and CM are employees of WIG2 GmbH. JK\u00f6, LK, CS, IH and AK are employed by Pfizer Pharma GmbH. JKi has received grants for consultancy and educational activities from Italfarmaco, Pfizer, Roche, Santhera, and Sarepta. AP reports financial compensation for training activities and research grants from Novartis and Biogen. The authors report no other conflicts of interest in this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No primary patient data was collected for the conduct of this research. According to the 10th chapter of book V of social code in Germany (SGB V, Sozialgesetzbuch), anonymized healthcare claims data can be used for research purposes, therefore ethics approval of this secondary data were not required. Only WIG2 employees were granted access to the data for the research, and only aggregated results were generated and presented.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"This work has not been published previously, and it is not under consideration for publication elsewhere. If accepted, it will not be published elsewhere in the same form in English or in any other language including electronically, without the written consent of the copyright holder. The publication and all data, visualizations and content have been approved for publication by all authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"429"}}